These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37289642)

  • 1. Point-of-care ultronography can help detect subclinical hemarthrosis in hemophilic patients undergoing regular optimal clotting factor prophylaxis to achieve zero bleeding.
    Rodriguez-Merchan EC
    Expert Rev Hematol; 2023; 16(8):565-566. PubMed ID: 37289642
    [No Abstract]   [Full Text] [Related]  

  • 2. How I use bypassing therapy for prophylaxis in patients with hemophilia A and inhibitors.
    Leissinger CA; Singleton T; Kruse-Jarres R
    Blood; 2015 Jul; 126(2):153-9. PubMed ID: 25827834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemophilic arthropathy: how to diagnose subclinical bleeding early and how to orthopedically treat a damaged joint.
    Rodriguez-Merchan EC
    Expert Rev Hematol; 2023; 16(9):651-658. PubMed ID: 37392151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
    Stobart K; Iorio A; Wu JK
    Cochrane Database Syst Rev; 2006 Apr; (2):CD003429. PubMed ID: 16625581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylaxis in congenital coagulation disorders: past, present and future.
    Mannucci PM
    Blood Transfus; 2008 Sep; 6 Suppl 2(Suppl 2):s1-3. PubMed ID: 19105502
    [No Abstract]   [Full Text] [Related]  

  • 6. [Status of joint and intracranial bleeding of moderate and severe hemophilia in children under on-demand therapy].
    He WW; Wu RH
    Zhonghua Er Ke Za Zhi; 2012 Aug; 50(8):636-8. PubMed ID: 23158747
    [No Abstract]   [Full Text] [Related]  

  • 7. Limitations of prophylactic treatment in patients with hemophilia.
    López Fernández MF
    Blood Coagul Fibrinolysis; 2019 Sep; 30(1S Suppl 1):S22-S24. PubMed ID: 31157677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
    Stobart K; Iorio A; Wu JK
    Cochrane Database Syst Rev; 2005 Apr; (2):CD003429. PubMed ID: 15846666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B.
    Olasupo OO; Lowe MS; Krishan A; Collins P; Iorio A; Matino D
    Cochrane Database Syst Rev; 2021 Aug; 8(8):CD014201. PubMed ID: 34407214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
    Iorio A; Marchesini E; Marcucci M; Stobart K; Chan AK
    Cochrane Database Syst Rev; 2011 Sep; (9):CD003429. PubMed ID: 21901684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Personalized prophylaxis in people with hemophilia A: challenges and achievements.
    Ar MC; Baslar Z; Soysal T
    Expert Rev Hematol; 2016 Dec; 9(12):1203-1208. PubMed ID: 27809624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylaxis in haemophilia patients with inhibitors.
    Leissinger CA
    Haemophilia; 2006 Dec; 12 Suppl 6():67-72; discussion 72-3. PubMed ID: 17123397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project.
    Manco-Johnson MJ; Soucie JM; Gill JC;
    Blood; 2017 Apr; 129(17):2368-2374. PubMed ID: 28183693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current challenges in the management of hemophilia.
    Bauer KA
    Am J Manag Care; 2015 Mar; 21(6 Suppl):S112-22. PubMed ID: 26168206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current concepts in diagnosis and management of hemophilia.
    Aledort LM
    Hosp Pract (Off Ed); 1982 Oct; 17(10):77-84, 89-92. PubMed ID: 6811410
    [No Abstract]   [Full Text] [Related]  

  • 16. Including the life-time cumulative number of joint bleeds in the definition of primary prophylaxis.
    den Uijl IE; Fischer K
    Thromb Haemost; 2008 May; 99(5):965; author reply 966-8. PubMed ID: 18449430
    [No Abstract]   [Full Text] [Related]  

  • 17. Prophylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for different clinical situations.
    Jiménez-Yuste V; Alvarez MT; Martín-Salces M; Quintana M; Rodriguez-Merchan C; Lopez-Cabarcos C; Velasco F; Hernández-Navarro F
    Haemophilia; 2009 Jan; 15(1):203-9. PubMed ID: 19149850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Joint Aspiration for Acute Hemarthrosis in Children Receiving Factor VIII Prophylaxis for Severe Hemophilia: 11-year Safety Data.
    Manners PJ; Price P; Buurman D; Lewin B; Smith B; Cole CH
    J Rheumatol; 2015 May; 42(5):885-90. PubMed ID: 25729030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemophilic arthropathy: Current knowledge and future perspectives.
    Gualtierotti R; Solimeno LP; Peyvandi F
    J Thromb Haemost; 2021 Sep; 19(9):2112-2121. PubMed ID: 34197690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylaxis: the next haemophilia treatment.
    Aledort LM
    J Intern Med; 1992 Jul; 232(1):1-2. PubMed ID: 1640188
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.